VivoSeq
Oncology

Leptomeningeal Metastases

1

Pipeline Programs↗

13

Active Trials↗

1

Companies Involved↗

Leptomeningeal Metastases is an early-stage landscape with 1 program across 1 company. The most active players are Plus Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Plus Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

186rnl

NYU Langone Health

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

20

clinical trials

Recruiting5 · 25%
Completed5 · 25%
Not yet recruiting5 · 25%
Active, not recruiting3 · 15%
Unknown status1 · 5%
Terminated1 · 5%

Clinical Trials

Trial Activity

20 trials

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06440954·220 enrolled
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Recruiting·SShanghai Chest Hospital·Phase 1·NCT06663306·19 enrolled
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Recruiting·PPlus Therapeutics·Phase 1·NCT07098806·24 enrolled
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT07092202·40 enrolled
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07304739·30 enrolled
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
Active, not recruiting·—·Phase 1·NCT03696030·24 enrolled
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04192981·21 enrolled
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Active, not recruiting·PPlus Therapeutics·Phase 1·NCT05034497·18 enrolled
Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs
Not yet recruiting·JJiangsu Province Nanjing Brain Hospital·N/A·NCT06766591·36 enrolled
Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases
Not yet recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06861218·42 enrolled
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Not yet recruiting·GGuangdong Association of Clinical Trials·Phase 4·NCT06282874·50 enrolled
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
Not yet recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06537297·30 enrolled
A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases
Not yet recruiting·NNYU Langone Health·Phase 1·NCT07674693·29 enrolled
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Completed·KKadmon Corporation, LLC·Phase 2·NCT02616393·36 enrolled
Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors
Completed·TThe First Hospital of Jilin University·Phase 2·NCT03082144·53 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)